Curetis To Attend Key Conferences in the Fourth Quarter of 2019
October 30, 2019 05:00 ET
|
Curetis
Amsterdam, the Netherlands, and Holzgerlingen, Germany, October 30, 2019, 10:00 am CET - Curetis N.V. (the "Company" and, together with its subsidiaries, "Curetis"), a developer of next-level...
Curetis Group Company Ares Genetics Launches AI-powered Molecular Antibiotic Susceptibility Test
October 28, 2019 02:46 ET
|
Curetis
Blinded evaluation study with leading global IVD player demonstrated diagnostic performance in line with FDA requirements for antibiotic susceptibility testing (AST)Already received orders for...
Curetis Reports Financial Results for the First Six Months of 2019
September 18, 2019 01:53 ET
|
Curetis
- Strategic transaction to combine businesses with OpGen Inc. - Revenues increased by approximately 35% year-on-year - Progressing regulatory product approvals in the U.S. and China Amsterdam,...
Curetis Group Subsidiary Ares Genetics Signs R&D and Option Agreement with Leading Global IVD Corporation
September 16, 2019 01:46 ET
|
Curetis
R&D collaboration to develop NGS-based predictive antibiotic resistance testing powered by ARESdbPartner to fund R&D and obtains option to license ARESdb and ARES Technology Platform for...
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses
September 04, 2019 02:24 ET
|
Curetis
Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for...
Curetis Retains H.C. Wainwright & Co. as Strategic Advisor
August 12, 2019 01:59 ET
|
Curetis
Investment bank supports Curetis in assessment of all strategic and tactical financing options Publication of H1-2019 financials postponed to September 18, 2019Key financials show EUR 7.8...
Curetis Group Company Ares Genetics Launches Service Laboratory for NGS-based Molecular Drug Resistance Testing
August 08, 2019 01:59 ET
|
Curetis
Initial focus on non-diagnostic testing with Next Generation Sequencing (NGS) for infection control, outbreak management and researchFirst commercial orders received and processed Vienna,...
Curetis Elects Share Settlement for Excess Entitlement Under First Tranche of Yorkville Convertible Notes
August 01, 2019 01:58 ET
|
Curetis
- Share issue cap of 2.75 million shares under the first tranche of EUR 5 million in Yorkville convertible bonds has been reached - Curetis elects to settle the excess entitlement under the first...
Curetis and AKO MED Ink Distribution Agreement Covering Four Countries in CEE Region
July 30, 2019 02:01 ET
|
Curetis
- AKO MED to exclusively distribute Unyvero A50 portfolio in Serbia, North Macedonia, Bosnia Hercegovina, and Montenegro - Preparing inclusion of Unyvero in several regional tender offers ...
Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
July 25, 2019 02:00 ET
|
Curetis
Amsterdam, the Netherlands, San Diego, CA, USA, and Holzgerlingen, Germany, July 25, 2019, 08:00 am CEST - Curetis N.V. (the "Company" and, together with Curetis USA Inc. and Curetis GmbH,...